US · Healthcare

Hemagen Diagnostics Inc (HMGN)

Biotechnology

Hemagen Diagnostics Inc (HMGN) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-03-24, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for HMGN

P/E ratio

18.00

Hemagen Diagnostics Inc (HMGN) — FAQ

What is HMGN's P/E ratio?

The price-to-earnings (P/E) ratio for Hemagen Diagnostics Inc (HMGN) is 18.00 (data as of 2026-03-24).

Does Hemagen Diagnostics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Hemagen Diagnostics Inc (HMGN). Check the MyAverix Finance app for the latest dividend data.

What sector is Hemagen Diagnostics Inc in?

Hemagen Diagnostics Inc (HMGN) is classified in the Healthcare sector (Biotechnology industry).

What exchange is HMGN listed on?

HMGN is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)